Ionis Pharmaceuticals Announces Positive Results in Familial Chylomicronemia Syndrome
This week Ionis Pharmaceuticals, Inc. issued a press release via PRNewswire announcing topline Phase 3 results for its Balance study of olezarsen. The study ( NCT04568434 ) enrolled people with…